Clinical Management of Migraine

Overview

Journal J Clin Med

Specialty General Medicine

Date 2022 Sep 9

PMID 36079154

Authors

Maria Albanese

Affiliations

Soon will be listed here.

Abstract

Migraine is one of the most frequent neurological and vascular disorders, with an estimated global prevalence of 14 [...].

Citing Articles

Poor Adherence to the Mediterranean Diet and Sleep Disturbances Are Associated with Migraine Chronification and Disability among an Adult Population in the Lazio Region, Italy.

Bovenzi R, Noce A, Conti M, Di Lauro M, Chiaramonte B, Della Morte D Nutrients. 2024; 16(13).

PMID: 38999916 PMC: 11243412. DOI: 10.3390/nu16132169.

Early Wearing-Off Effect of OnabotulinumtoxinA in Chronic Migraine: A Prospective Real-Life Study.

Rodriguez-Montolio J, Navarro-Perez M, Almeida-Zurita M, Santos-Lasaosa S J Clin Med. 2023; 12(16).

PMID: 37629402 PMC: 10455650. DOI: 10.3390/jcm12165360.

Risk of Migraine after Traumatic Brain Injury and Effects of Injury Management Levels and Treatment Modalities: A Nationwide Population-Based Cohort Study in Taiwan.

Chen M, Sung Y, Chien W, Chung C, Chen J J Clin Med. 2023; 12(4).

PMID: 36836064 PMC: 9959615. DOI: 10.3390/jcm12041530.

References

Favoni V, Giani L, Al-Hassany L, Asioli G, Butera C, de Boer I . CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?. J Headache Pain. 2019; 20(1):27. PMC: 6734543. DOI: 10.1186/s10194-019-0979-y. View

Sacco S, Amin F, Ashina M, Bendtsen L, Deligianni C, Gil-Gouveia R . European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain. 2022; 23(1):67. PMC: 9188162. DOI: 10.1186/s10194-022-01431-x. View

Viticchi G, Falsetti L, Silvestrini M, Bartolini M . Ditans: a new prospective for the therapy of migraine attack?. Neurol Sci. 2022; 43(9):5709-5716. DOI: 10.1007/s10072-022-06260-z. View

Ambrosini A, Schoenen J . Invasive pericranial nerve interventions. Cephalalgia. 2016; 36(12):1156-1169. DOI: 10.1177/0333102416639515. View

Charles A . The pathophysiology of migraine: implications for clinical management. Lancet Neurol. 2017; 17(2):174-182. DOI: 10.1016/S1474-4422(17)30435-0. View

Mallick-Searle T, Moriarty M . Unmet needs in the acute treatment of migraine attacks and the emerging role of calcitonin gene-related peptide receptor antagonists: An integrative review. J Am Assoc Nurse Pract. 2020; 33(6):419-428. DOI: 10.1097/JXX.0000000000000397. View

Altamura C, Brunelli N, Marcosano M, Fofi L, Vernieri F . Gepants - a long way to cure: a narrative review. Neurol Sci. 2022; 43(9):5697-5708. PMC: 9159895. DOI: 10.1007/s10072-022-06184-8. View

Barbanti P, Egeo G, Aurilia C, dOnofrio F, Albanese M, Cetta I . Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study). J Headache Pain. 2022; 23(1):46. PMC: 8994302. DOI: 10.1186/s10194-022-01396-x. View

Coppola G, Di Lorenzo C, Serrao M, Parisi V, Schoenen J, Pierelli F . Pathophysiological targets for non-pharmacological treatment of migraine. Cephalalgia. 2015; 36(12):1103-1111. DOI: 10.1177/0333102415620908. View

10.

. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396(10258):1204-1222. PMC: 7567026. DOI: 10.1016/S0140-6736(20)30925-9. View

11.

Altamura C, Brunelli N, Marcosano M, Aurilia C, Egeo G, Lovati C . Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience. J Neurol. 2022; 269(11):5848-5857. PMC: 9243974. DOI: 10.1007/s00415-022-11226-4. View

12.

Steiner T, Stovner L, Jensen R, Uluduz D, Katsarava Z . Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020; 21(1):137. PMC: 7708887. DOI: 10.1186/s10194-020-01208-0. View

13.

Sacco S, Braschinsky M, Ducros A, Lampl C, Little P, Brink A . European headache federation consensus on the definition of resistant and refractory migraine : Developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain. 2020; 21(1):76. PMC: 7296705. DOI: 10.1186/s10194-020-01130-5. View

14.

Lipton R, Bigal M . Migraine: epidemiology, impact, and risk factors for progression. Headache. 2005; 45 Suppl 1:S3-S13. DOI: 10.1111/j.1526-4610.2005.4501001.x. View

15.

Ray J, Allen P, Bacsi A, Bosco J, Chen L, Eller M . Inflammatory complications of CGRP monoclonal antibodies: a case series. J Headache Pain. 2021; 22(1):121. PMC: 8501661. DOI: 10.1186/s10194-021-01330-7. View

16.

Altamura C, Cevoli S, Brunelli N, Aurilia C, Fofi L, Egeo G . When should we consider chronic patients as non-responders to monoclonal antibodies targeting the CGRP pathway?. J Neurol. 2021; 269(2):1032-1034. DOI: 10.1007/s00415-021-10772-7. View

17.

Albanese M, Mercuri N . Could the New Anti-CGRP Monoclonal Antibodies Be Effective in Migraine Aura? Case Reports and Literature Review. J Clin Med. 2022; 11(5). PMC: 8911201. DOI: 10.3390/jcm11051228. View

18.

Kim Y, Granstein R . Roles of calcitonin gene-related peptide in the skin, and other physiological and pathophysiological functions. Brain Behav Immun Health. 2021; 18:100361. PMC: 8551410. DOI: 10.1016/j.bbih.2021.100361. View